<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546104</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00007578</org_study_id>
    <secondary_id>BMS CA180089</secondary_id>
    <nct_id>NCT00546104</nct_id>
  </id_info>
  <brief_title>Phase II Dasatinib Study in Advanced Breast Cancer</brief_title>
  <official_title>A Phase II Trial of Dasatinib to Treat Women With Stage IV or Inoperable Stage III Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if dasatinib will safely reduce the size or spread
      of your tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The introduction of biologics with specific molecular targets has initiated a trend toward
      improved survival in women with metastatic breast cancer.

      The tyrosine kinase SRC (pp60src) is a member of a family of proteins that contribute to
      cellular signal transduction activities such as cell growth, differentiation, survival,
      adhesion and migration. Abnormal signaling has been linked to cancer metastases; thus,
      identification of molecular regulators or inhibitors of SRC present therapeutic opportunity
      for cancer patients. Src kinases consist of eight non-receptor tyrosine kinases (Src, Fyn,
      Yes, Lck, Lyn, Hck, Fgr and Blk) that interact with the intracellular domains of growth
      factor/cytokine receptors, (G-protein-coupled receptor)GPCRs and integrins.

      Inhibition of SRC has also been associated with reversal of chemoresistance and restored
      sensitivity to drug-resistant ovarian cancer cells, suggesting potential as second- line
      treatment for previously treated populations. Dasatinib is a potent, broad spectrum inhibitor
      of 5 critical oncogenic tyrosine kinases, including SRC.

      Patients will receive dasatinib, a Src inhibitor, at an initial dose of 50 mg PO BID, with
      real-time PharmacoDynamic dose adjustment following 4 weeks of therapy based on inhibition of
      phosphorylation of SRC, focal adhesion kinase (FAK) and paxillin, until progression. The
      primary objective is to assess tolerability and estimate the proportion of patients who are
      progression-free at 16 weeks from the date of study enrollment.

      A minimum of 2 (maximum of 3) tumor biopsies will be analyzed and compared for SRC signature:
      one at baseline (study enrollment, all patients); the second after 4 weeks of dasatinib
      therapy (all patients); and the third at progression (only patients who progress after a
      documented response).

      Patients will receive continuous daily administration until documented disease progression,
      and will be followed until death.

      The results of this study may be useful in designing future studies using dasatinib alone or
      in combination with chemotherapy, thus having the potential to alter the current standard of
      care in this incurable population.

      Additional correlative studies will be conducted. Tumor biopsies will be analyzed and
      compared for SRC, pSRC, Ki67, and related genomic signatures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of the Proportion of Progression-free Patients at 16 Wks.</measure>
    <time_frame>16 weeks</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or measurable increase in a non-target lesion, or the appearance of new lesions, or similar definition as appropriate.
Proportion progression-free at 16 weeks.From first day of study related treatment with Dasatinib until the date of first documented progression or date of death from any cause, whichever came first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Measure Response to Protocol Therapy Per RECIST Criteria</measure>
    <time_frame>16 weeks</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Progression At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as a reference the smallest sum longest diameter recorded since treatment started, or the appearance of one or more new lesions.
RECIST 1.0 Overall response:
Complete Response (CR) Partial Response (PR) Stable Disease (SD) Progressive Disease (PD)
CR= CR+CR and No new lesions PR= CR+SD; PR+SD and no new lesions SD= SD+SD and no new lesions PD= PD+any new lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization and Comparison of SRC (A Protein Tyrosine Kinase)Dysregulation at Baseline (All Patients), After 4 Weeks of Dasatinib Treatment (All Patients), and at Progression (Only Patients Who Progress After Documented Response)</measure>
    <time_frame>4 weeks</time_frame>
    <description>For the 20 patients with evaluable biopsies at baseline and week 4, the median relative change from baseline in tissue biomarker levels of phospho-Src (p-Src)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate SRC Dysregulation Results With Response to Dasatinib Therapy</measure>
    <time_frame>16 weeks</time_frame>
    <description>Since all patients progressed there is no comparison to between responders and non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Explore the Association Between Each Patient's SRC Signature and Their Time to Progression.</measure>
    <time_frame>Baseline Src measure to first progression</time_frame>
    <description>Spearman's correlation between the change in SRC signature from baseline to 4 weeks and time to progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Explore the Association Between Dasatinib and Osteoclastic Bone Resorption</measure>
    <time_frame>not assessed</time_frame>
    <description>Not assessed secondary to limited number of subjects.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Dasatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50- 100 mg PO BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.</description>
    <arm_group_label>Dasatinib</arm_group_label>
    <other_name>Sprycel</other_name>
    <other_name>BMS-354825</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Measurable Stage IV or inoperable Stage III advanced breast cancer.

          -  There is no limit on the number of prior therapies.

          -  At least 3 weeks since prior chemotherapy, biological or hormonal therapy.

          -  At least 2 weeks since surgical biopsy.

          -  At least 3 weeks since major (open thoracic/abdominal/cardiac) surgery.

          -  No central nervous system (CNS) metastases except solitary brain metastasis

          -  No cardiac dysfunction

          -  left ventricular ejection fraction (LVEF) â‰¥ 50% as determined by multiple gated
             acquisition scan (MUGA)/echocardiogram

          -  Adequate blood counts

          -  Normal liver and kidney function

          -  Negative serum pregnancy test.

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Pregnant or breast feeding.

          -  Prior treatment with dasatinib.

          -  Bone as the only site of disease.

          -  Significant gastrointestinal bleeding

          -  Septicemia, infection, acute hepatitis, hypokalemia, or hypomagnesemia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Blackwell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palm Beach Cancer Center Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Health Care</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2007</study_first_posted>
  <results_first_submitted>January 22, 2013</results_first_submitted>
  <results_first_submitted_qc>July 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 17, 2013</results_first_posted>
  <last_update_submitted>July 15, 2013</last_update_submitted>
  <last_update_submitted_qc>July 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Breast Cancer</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Dasatinib</keyword>
  <keyword>Inoperable Stage III Breast Cancer</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Stage IV Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects will be identified in cancer center outpatient clinics multi-site. The study will be introduced by a physician or caregiver known to the patient. We will need to review protected health information in order to identify subjects, and information resulting from this activity will be used only to assess eligibility of a subject.</recruitment_details>
      <pre_assignment_details>Meds which inhibit platelet function/coagulation,potent inhibitors of cytochrome CYP3A, or meds that prolong the QT interval during study require a 7 day wash-out.IV bisphosphonates must be held for 2 wks before/6 wks after trial tx. Subjects must be 3 wks since prior to therapy, 2 wks since surgical bx and 3 wks since major surgery.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dasatinib</title>
          <description>50-100 mg PO BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dasatinib</title>
          <description>50-100mg by mouth twice a day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.4" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Estimation of the Proportion of Progression-free Patients at 16 Wks.</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or measurable increase in a non-target lesion, or the appearance of new lesions, or similar definition as appropriate.
Proportion progression-free at 16 weeks.From first day of study related treatment with Dasatinib until the date of first documented progression or date of death from any cause, whichever came first.</description>
        <time_frame>16 weeks</time_frame>
        <population>31 patients on this trial, 1 patient was found to have disease progression at 16-weeks, 16 patients had disease progression prior to 16 weeks, 8 patients were taken off-treatment due to toxicity, and 6 patients voluntarily withdrew from treatment. These latter two groups of patients were censored in the analysis of Progression Free Survival.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>50mg-100mg po BID</description>
          </group>
        </group_list>
        <measure>
          <title>Estimation of the Proportion of Progression-free Patients at 16 Wks.</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or measurable increase in a non-target lesion, or the appearance of new lesions, or similar definition as appropriate.
Proportion progression-free at 16 weeks.From first day of study related treatment with Dasatinib until the date of first documented progression or date of death from any cause, whichever came first.</description>
          <population>31 patients on this trial, 1 patient was found to have disease progression at 16-weeks, 16 patients had disease progression prior to 16 weeks, 8 patients were taken off-treatment due to toxicity, and 6 patients voluntarily withdrew from treatment. These latter two groups of patients were censored in the analysis of Progression Free Survival.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Measure Response to Protocol Therapy Per RECIST Criteria</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Progression At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as a reference the smallest sum longest diameter recorded since treatment started, or the appearance of one or more new lesions.
RECIST 1.0 Overall response:
Complete Response (CR) Partial Response (PR) Stable Disease (SD) Progressive Disease (PD)
CR= CR+CR and No new lesions PR= CR+SD; PR+SD and no new lesions SD= SD+SD and no new lesions PD= PD+any new lesions</description>
        <time_frame>16 weeks</time_frame>
        <population>Proportion with Best Response of Stable Disease</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>50mg-100mg po BID</description>
          </group>
        </group_list>
        <measure>
          <title>To Measure Response to Protocol Therapy Per RECIST Criteria</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Progression At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as a reference the smallest sum longest diameter recorded since treatment started, or the appearance of one or more new lesions.
RECIST 1.0 Overall response:
Complete Response (CR) Partial Response (PR) Stable Disease (SD) Progressive Disease (PD)
CR= CR+CR and No new lesions PR= CR+SD; PR+SD and no new lesions SD= SD+SD and no new lesions PD= PD+any new lesions</description>
          <population>Proportion with Best Response of Stable Disease</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization and Comparison of SRC (A Protein Tyrosine Kinase)Dysregulation at Baseline (All Patients), After 4 Weeks of Dasatinib Treatment (All Patients), and at Progression (Only Patients Who Progress After Documented Response)</title>
        <description>For the 20 patients with evaluable biopsies at baseline and week 4, the median relative change from baseline in tissue biomarker levels of phospho-Src (p-Src)</description>
        <time_frame>4 weeks</time_frame>
        <population>Twenty patients with evaluable biopsies at baseline and 4 week follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>50mg-100mg po BID</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization and Comparison of SRC (A Protein Tyrosine Kinase)Dysregulation at Baseline (All Patients), After 4 Weeks of Dasatinib Treatment (All Patients), and at Progression (Only Patients Who Progress After Documented Response)</title>
          <description>For the 20 patients with evaluable biopsies at baseline and week 4, the median relative change from baseline in tissue biomarker levels of phospho-Src (p-Src)</description>
          <population>Twenty patients with evaluable biopsies at baseline and 4 week follow-up</population>
          <units>percentage of change in p-SRC</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.125" lower_limit="-0.41" upper_limit="0.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The median change in SRC from baseline to 4 weeks was estimated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3</p_value>
            <p_value_desc>The p-value is from a paired t-test to test the null hypothesis the mean relative change in Src from baseline to 4 weeks is equal to zero.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30</ci_lower_limit>
            <ci_upper_limit>9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlate SRC Dysregulation Results With Response to Dasatinib Therapy</title>
        <description>Since all patients progressed there is no comparison to between responders and non-responders.</description>
        <time_frame>16 weeks</time_frame>
        <population>20 patients with baseline and 4 week Src measures. 11 patients came off due to screen failure, toxicity or progression before 4 week biopsy.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>50mg-100mg po BID</description>
          </group>
        </group_list>
        <measure>
          <title>Correlate SRC Dysregulation Results With Response to Dasatinib Therapy</title>
          <description>Since all patients progressed there is no comparison to between responders and non-responders.</description>
          <population>20 patients with baseline and 4 week Src measures. 11 patients came off due to screen failure, toxicity or progression before 4 week biopsy.</population>
          <units>percentage change in p-SRC</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.10" lower_limit="-.30" upper_limit=".10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-.30</ci_lower_limit>
            <ci_upper_limit>.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Explore the Association Between Each Patient's SRC Signature and Their Time to Progression.</title>
        <description>Spearman's correlation between the change in SRC signature from baseline to 4 weeks and time to progression</description>
        <time_frame>Baseline Src measure to first progression</time_frame>
        <population>11 patients had both change in Src level and progression time intervals</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>50mg-100mg po BID</description>
          </group>
        </group_list>
        <measure>
          <title>To Explore the Association Between Each Patient's SRC Signature and Their Time to Progression.</title>
          <description>Spearman's correlation between the change in SRC signature from baseline to 4 weeks and time to progression</description>
          <population>11 patients had both change in Src level and progression time intervals</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Explore the Association Between Dasatinib and Osteoclastic Bone Resorption</title>
        <description>Not assessed secondary to limited number of subjects.</description>
        <time_frame>not assessed</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>50mg-100mg po BID</description>
          </group>
        </group_list>
        <measure>
          <title>To Explore the Association Between Dasatinib and Osteoclastic Bone Resorption</title>
          <description>Not assessed secondary to limited number of subjects.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dasatinib</title>
          <description>50-100mg po bid</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema, limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pain, back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pain, extrimity limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pain, chest/thorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>fever: non-neutropenic</sub_title>
                <description>number of subjects effected: Grade 1=3 grade 2=2 grade 3=0</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>number of subjects effected: Grade 1=10 grade 2=5 grade 3=0</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <description>number of subjects effected: Grade 1=8 grade 2=3 grade 3=0</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>number of subjects effected: Grade 1=10 grade 2=8 grade 3=1</description>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <description>number of subjects effected: Grade 1=10 grade 2=3 grade 3=0</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>pain: abdomen</sub_title>
                <description>number of subjects effected: Grade 1=6 grade 2=0 grade 3=0</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <description>grade 1 19% grade 2 13% grade 3 10%</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <description>number of subject effected: Grade 1=7 grade 2=8 grade 3=1</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <description>number of subjects effected: Grade 1=5 grade 2=2 grade 3=0</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <description>number of subjects effected: Grade 1=6 grade 2=2 grade 3=0</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>edema:facial</sub_title>
                <description>number of subjects effected: Grade 1=4 grade 2=1 grade 3=0</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>edema: extremity</sub_title>
                <description>number of subjects effected: Grade 1=5 grade 2=1 grade 3=0</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>rhinitis</sub_title>
                <description>number of subjects effected: Grade 1=5 grade 2=0 grade 3=0</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>elevated ALT</sub_title>
                <description>number of subjects effected: Grade 1=4 grade 2=1 grade 3=0</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>elevated AST</sub_title>
                <description>number of subjects effected: Grade 1=2 grade 2=0 grade 3=0</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>hyponatremia</sub_title>
                <description>number of subjects effected: Grade 1=1 grade 2=0 grade 3=1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <description>number of subjects effected: Grade 1=0 grade 2=1 grade 3=1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain: bone</sub_title>
                <description>number of subjects effected: Grade 1=5 grade 2=0 grade 3=1</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>pain:extremity</sub_title>
                <description>number of subjects effected: Grade 1=3 grade 2=2 grade 3=1</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>pain:joint</sub_title>
                <description>number of subjects effected: Grade 1=4 grade 2=3 grade 3=2</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>pain: muscle</sub_title>
                <description>number of subjects effected: Grade 1=1 grade 2=3 grade 3=0</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>pain: headache</sub_title>
                <description>number of subjects effected: Grade 1=9 grade 2=2 grade 3=0</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>neuropathy sensory</sub_title>
                <description>number of subjects effected: Grade 1=7 grade 2=2 grade 3=0</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <description>number of subjects effected: Grade 1=6 grade 2=0 grade 3=0</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <description>number of subjects effected: Grade 1=4 grade 2=5 grade 3=3</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>pneumonitis</sub_title>
                <description>number of subjects effected: Grade 1=0 grade 2=1 grade 3=2</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>paricardial effusion</sub_title>
                <description>number of subjects effected: Grade 1=2 grade 2=0 grade 3=0</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>plueral effusion</sub_title>
                <description>number of subjects effected: Grade 1=5 grade 2=8 grade 3=3</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain: chestwall</sub_title>
                <description>number of subjects effected: Grade 1=2 grade 2=2 grade 3=0</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>cellulitis</sub_title>
                <description>number of subjects effected: Grade 1=0 grade 2=0 grade 3=1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <description>number of subjects effected: Grade 1=14 grade 2=2 grade 3=0</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>mucositis</sub_title>
                <description>number of subjects effected: Grade 1=4 grade 2=0 grade 3=0</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DVT</sub_title>
                <description>number of subjects effected: Grade 1=0 grade 2=0 grade 3=2</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kimberly Blackwell, MD</name_or_title>
      <organization>Duke University Health System</organization>
      <phone>919-668-1478</phone>
      <email>kimberly.blackwell@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

